Atlas FDA

RESTYLANE INJECTABLE GEL

FDA premarket approval P040024/S052 · decided 2011-07-18

Approval details

PMA number
P040024
Supplement
S052
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
RESTYLANE INJECTABLE GEL
Generic name
Implant, dermal, for aesthetic use
Applicant
Q-Med AB
Date received
2011-01-28
Decision date
2011-07-18
Days to decision
171 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Uppsala
Statement
APPROVAL FOR AN EXTENSION TO THE EXPIRATION DATE OF THE LIDOCAINE HYDROCHLORIDE RAW MATERIAL FROM 12 MONTHS TO 24 MONTHS.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.